390 related articles for article (PubMed ID: 16943316)
41. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats.
Lim G; Sung B; Ji RR; Mao J
Pain; 2003 Sep; 105(1-2):275-83. PubMed ID: 14499445
[TBL] [Abstract][Full Text] [Related]
42. Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.
Zhu CZ; Mikusa JP; Fan Y; Hollingsworth PR; Pai M; Chandran P; Daza AV; Yao BB; Dart MJ; Meyer MD; Decker MW; Hsieh GC; Honore P
Br J Pharmacol; 2009 Jun; 157(4):645-55. PubMed ID: 19371344
[TBL] [Abstract][Full Text] [Related]
43. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses.
Strangman NM; Walker JM
J Neurophysiol; 1999 Jul; 82(1):472-7. PubMed ID: 10400973
[TBL] [Abstract][Full Text] [Related]
44. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
45. Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms.
Hough LB; Svokos K; Nalwalk JW
Brain Res; 2009 Jan; 1247():62-70. PubMed ID: 18983834
[TBL] [Abstract][Full Text] [Related]
46. Physiological evidence of a postsynaptic inhibition of the tail flick reflex by a cannabinoid receptor agonist.
Dableh LJ; Yashpal K; Henry JL
Eur J Pharmacol; 2009 Jan; 602(1):36-40. PubMed ID: 19027734
[TBL] [Abstract][Full Text] [Related]
47. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model.
Cui JH; Kim WM; Lee HG; Kim YO; Kim CM; Yoon MH
Neurosci Lett; 2011 Apr; 493(3):67-71. PubMed ID: 21195743
[TBL] [Abstract][Full Text] [Related]
48. The effect of ABT-702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury.
Suzuki R; Stanfa LC; Kowaluk EA; Williams M; Jarvis MF; Dickenson AH
Br J Pharmacol; 2001 Apr; 132(7):1615-23. PubMed ID: 11264257
[TBL] [Abstract][Full Text] [Related]
49. Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells.
Burgos E; Gómez-Nicola D; Pascual D; Martín MI; Nieto-Sampedro M; Goicoechea C
Eur J Pharmacol; 2012 May; 682(1-3):62-72. PubMed ID: 22374260
[TBL] [Abstract][Full Text] [Related]
50. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
51. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat.
Coruzzi G; Adami M; Coppelli G; Frati P; Soldani G
Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):715-8. PubMed ID: 10619190
[TBL] [Abstract][Full Text] [Related]
52. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
54. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
55. Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo.
Kelly S; Chapman V
J Neurophysiol; 2001 Dec; 86(6):3061-4. PubMed ID: 11731561
[TBL] [Abstract][Full Text] [Related]
56. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
Kehl LJ; Hamamoto DT; Wacnik PW; Croft DL; Norsted BD; Wilcox GL; Simone DA
Pain; 2003 May; 103(1-2):175-86. PubMed ID: 12749972
[TBL] [Abstract][Full Text] [Related]
57. Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats.
Germanò MP; D'Angelo V; Mondello MR; Pergolizzi S; Capasso F; Capasso R; Izzo AA; Mascolo N; De Pasquale R
Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):241-4. PubMed ID: 11218077
[TBL] [Abstract][Full Text] [Related]
58. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system.
Palazzo E; de Novellis V; Petrosino S; Marabese I; Vita D; Giordano C; Di Marzo V; Mangoni GS; Rossi F; Maione S
Eur J Neurosci; 2006 Oct; 24(7):2011-20. PubMed ID: 17040473
[TBL] [Abstract][Full Text] [Related]
59. Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A.
Pozzi O; Misiano P; Clark GD; Visentin L
Pharmacology; 2003 Nov; 69(3):158-63. PubMed ID: 14512703
[TBL] [Abstract][Full Text] [Related]
60. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat.
Scott DA; Wright CE; Angus JA
Pain; 2004 May; 109(1-2):124-31. PubMed ID: 15082134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
